Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops aesthetic and therapeutic dermatology products.
Year Established: | 5/05 |
Funding: | 25 |
Address: | Newark, CA 94560 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | (510) 742-3401 |
Mail: | info@revance.com |
Company URL: | http://www.revance.com |
At Revance Therapeutics Inc we have assembled a team of highly-motivated talented industry professionals dedicated to changing the way drugs are delivered. This is no small task but we believe it is possible and our team works every day to achieve it.
We are seeking exceptionally experienced individuals who will immediately contribute to the rapid development of our ambitious product pipeline. Passion creativity and a dedication to synthesizing products that improve lives and personal wellbeing are all a part of our culture.
As an entrepreneurial company Revance combines a dynamic start-up culture with the structure and stability of a larger corporation. This allows employees to work on exciting projects and technology within an infrastructure that provides guidance and security.
The foundation of our business is built upon teamwork and collaboration which enables us to achieve our goals. Our employees work effectively together to develop new processes and formulas that move the business forward.
Revance is located in Northern California (Newark) in the heart of Silicon Valley.
Check out the job opportunities in Job Openings.
Bio*One Capital,Essex Woodlands Health Ventures,Pac-Link Management Corporation,Palo Alto Investors,Shepherd Ventures,Technology Partners,Vivo Ventures
Dan Browne, Co-Founder, President & Chief Executive OfficerMr. Browne's career encompasses over 20 years of operating experience with biotherapeutic and device products. He served as President & CEO of Neomend (biologics) where he guided the company from discovery to human proof-of-concept and pivotal testing. Mr. Browne served as President & CEO of Prograft Medical (stent-grafts and drug delivery stents) where he established the company's first steady-state manufacturing facility, supported four stent-graft and stent projects from inception into Phase III studies, all four of which were approved for use by the US FDA and are now product leaders in the category. Previously, Mr. Browne served for more than 17 years at W.L. Gore and Associates, lastly as General Manager and Business Leader of W.L. Gore Medical Products Division, where he had direct P&L responsibility for worldwide cardiovascular and vascular products and he contributed to establishing the GORE-TEX brand as the global market leader.
Jacob Waugh, MD, Co-Founder & Chief Scientific OfficerDr. Waugh has over 14 years of experience in applied cross-disciplinary research. He trained with pioneering leaders in molecular medicine and chemistry, has received numerous awards, and has authored over 40 research manuscripts and publications. Dr. Waugh served as a Senior Scientist at Stanford University School of Medicine from 2001 to 2004, where he pioneered real-world in vivo tissue engineering applications. Dr. Waugh has also served as an advisor in the medical device and pharmaceutical industries.
David Styka, Chief Financial OfficerMr. Styka has over 20 years of finance and operations executive management experience and is a veteran of Silicon Valley's entrepreneurial environment, having raised in excess of $100 million for various companies. He has served as CFO of Equal Elements, a private equity management firm, CFO of The b-EQUAL Company, a family gaming company, a Partner at Incubasia, a Hong Kong based venture capital firm, and as CFO for Entercept, a network security firm acquired by McAfee. He has successfully completed 9 M&A transactions in the last 11 years.
Curtis Ruegg, Ph.D., Executive Vice President, Research & DevelopmentDr. Ruegg has more than 14 years of management responsibility for preclinical and product development including manufacturing across all company development programs (recombinant proteins, small molecules and semi-synthetics) as well as drug-device combinations, spanning pre-IND to post-approval stage programs with core participation in compilation/authoring CMC and nonclinical sections of regulatory filings and interactions (IND to NDA). Previously, Dr. Ruegg has held management and R&D positions at Co-Therix from 2004 to 2006 where he led the development effort for Ventavis